Novartis said on July 7, 2023 that a federal judge in Delaware had invalidated the main patent on Entresto. Its
Patent Dockets Show Loss of Exclusivity Years Before Sales Data Does Read Post »
Between 2016 and the second quarter of 2023, 43.0% of first-time generic entries in a sample of 146 oral-solid drugs
Authorized Generics vs. Your Forecast: The No-AG Assumption Fails 43% of the Time Read Post »
FDA counted 753 active pharmaceutical ingredient (API) facilities in the fee base for fiscal year 2027 generic drug fees. Of
The first generic Entresto reached US pharmacies on July 22, 2025. [1] Novartis had said in 2023 that the combination
The Second-Source Clock Starts Before the Patent Cliff Read Post »
On February 21, 2025, Teva announced the US launch of Selarsdi, a biosimilar to Johnson & Johnson’s Stelara. On February
Between 2025 and 2030, more than $300 billion in prescription drug revenue loses exclusivity. [1] Most of the dates are
Seven adalimumab biosimilars reached the US market in the same week of July 2023. [1] Two generic versions of Entresto
On October 9, 2025, Novo Nordisk confirmed that FDA had given its Bloomington, Indiana plant an Official Action Indicated (OAI)
Why the Best CDMOs Track Patent Litigation Dockets and the Rest Just Track Your PO Read Post »
The FDA approved Keytruda Qlex on September 19, 2025. [12] Merck lists the US expiry year of the original Keytruda
Sign in or create a free account to read this DrugPatentWatch article
